1:00 pm
Considerations for Platform Methods in Quality Control of Off-the-Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy products
Alice Lin
Associate Director, Quality Control , Fate Therapeutics
1:30 pm
Virtual Networking & Lunch
Developing Novel and Efficient Analytical Techniques for Development of Next Generation Cell Therapy Products
2:30 pm
Paving the Path Toward Well Characterized Allogeneic Cell Therapy Products
4:30 pm
CD19/22 Bi-Specific CAR T Clinical Trial Perspective: Understanding the Relationship Between the Manufacturing Process and the Final Cell Product
Shabnum Patel
Associate Director, Process Development & Manufacturing , Stanford Cancer Institute
5:00 pm
Determining Fluorescent Thresholds and Applying Fluorescent Threshold Gating to Flow Cytometry Methods in Clinical QC
Rebecca Brunette
Senior Manager, Cellular Phenotype, Product & Analytical Development , Bristol-Myers Squibb, Cell Therapy Development Organization
5:30 pm
Chairman’s Closing Remarks & Close of Day One